Adagene price target raised to $8 from $5 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Adagene (ADAG) to $8 from $5 and keeps a Buy rating on the shares. The company presented positive data from its ongoing Phase 1/2 study with ADG126, the analyst tells investors in a research note. The firm says safety and repeat dosing could be the differentiating factors.